Company Intelligence
Legend Biotech
传奇生物
No Known BCC Exposure
Legend Biotech is a drug innovator with its own manufacturing. NASDAQ-listed with US headquarters and manufacturing in New Jersey. In-house manufacturing insulates from CDMO-related BIOSECURE risk.
Overview
Legend Biotech (传奇生物) is the company behind ciltacabtagene autoleucel (Carvykti), a BCMA-targeting CAR-T cell therapy developed in partnership with Johnson & Johnson. Carvykti is one of the most successful China-originated cell therapies globally, approved by both FDA and EMA for relapsed/refractory multiple myeloma. Legend demonstrates that Chinese innovation extends beyond small molecules and antibodies into advanced cell therapy.
Key Facts
- Carvykti (cilta-cel) — one of the most commercially successful CAR-T therapies globally, $1B+ revenue trajectory
- Partnered with Johnson & Johnson (Janssen) for global development and commercialization
- FDA and EMA approved for relapsed/refractory multiple myeloma
- Own CAR-T manufacturing facilities in both China and the US (Somerset, NJ)
Key Deals
| Partner | Date | Value | Asset |
|---|---|---|---|
| Johnson & Johnson (Janssen) | 2017-ongoing | $350M upfront + royalties | Ciltacabtagene autoleucel (Carvykti) — global partnership |
Corporate Structure
Cayman Islands holding company, NASDAQ-listed. Subsidiary of GenScript Biotech (HK: 1548). US operations through Legend Biotech USA Inc. (Somerset, NJ). Manufacturing in both Nanjing and Somerset.